Anti-CCL21 antibody (ab9851)
Key features and details
- Rabbit polyclonal to CCL21
- Suitable for: IHC-P, Neutralising, Sandwich ELISA, WB, ELISA
- Reacts with: Human
- Isotype: unknown
Overview
-
Product name
Anti-CCL21 antibody
See all CCL21 primary antibodies -
Description
Rabbit polyclonal to CCL21 -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, Neutralising, Sandwich ELISA, WB, ELISAmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein corresponding to Human CCL21. Highly pure (>98%) recombinant human Exodus-2
Database link: O00585 -
Positive control
- Recombinant human CCL21 protein (ab9852) can be used as a positive control in WB.
-
General notes
Although some customers have been successful in IHC we no longer batch test in this application.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary. -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
No preservative, sterile filtered -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
unknown -
Light chain type
unknown -
Research areas
Associated products
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9851 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (2) |
Use at an assay dependent concentration.
|
Neutralising |
Use at an assay dependent concentration.
To yield one-half maximal inhibition [ND50] of the biological activity of human Exodus-2 (100 ng/ml), a concentration of 6.0 - 8.0 µg/ml of this antibody is required. |
|
Sandwich ELISA |
Use at an assay dependent concentration.
To detect CCL21-2 by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with a suitable detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant CCL21. |
|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 15 kDa.
To detect human Exodus-2 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant human Exodus-2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. |
|
ELISA |
Use at an assay dependent concentration.
To detect human Exodus-2 by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant human Exodus-2. |
Notes |
---|
IHC-P
Use at an assay dependent concentration. |
Neutralising
Use at an assay dependent concentration. To yield one-half maximal inhibition [ND50] of the biological activity of human Exodus-2 (100 ng/ml), a concentration of 6.0 - 8.0 µg/ml of this antibody is required. |
Sandwich ELISA
Use at an assay dependent concentration. To detect CCL21-2 by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5 - 2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with a suitable detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant CCL21. |
WB
Use at an assay dependent concentration. Predicted molecular weight: 15 kDa. To detect human Exodus-2 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant human Exodus-2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. |
ELISA
Use at an assay dependent concentration. To detect human Exodus-2 by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant human Exodus-2. |
Target
-
Function
Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs. -
Tissue specificity
Highly expressed in high endothelial venules of lymph nodes, spleen and appendix. Intermediate levels found in small intestine, thyroid gland and trachea. Low level expression in thymus, bone marrow, liver, and pancreas. Also found in tonsil, fetal heart and fetal spleen. -
Sequence similarities
Belongs to the intercrine beta (chemokine CC) family. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 6366 Human
- Omim: 602737 Human
- SwissProt: O00585 Human
- Unigene: 57907 Human
-
Alternative names
- 6Ckine antibody
- Beta chemokine exodus 2 antibody
- Beta-chemokine exodus-2 antibody
see all
Datasheets and documents
-
Datasheet download
References (7)
ab9851 has been referenced in 7 publications.
- Mu J et al. BRD4 promotes tumor progression and NF-?B/CCL2-dependent tumor-associated macrophage recruitment in GIST. Cell Death Dis 10:935 (2019). PubMed: 31819043
- Jiao X et al. The Diagnostic Value of Chemokine/Chemokine Receptor Pairs in Hepatocellular Carcinoma and Colorectal Liver Metastasis. J Histochem Cytochem 67:299-308 (2019). PubMed: 30633620
- Ha SK et al. Magnetic Resonance Imaging and Histopathological Visualization of Human Dural Lymphatic Vessels. Bio Protoc 8:N/A (2018). PubMed: 29780855
- Xiong Y et al. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. Oncotarget 8:25650-25659 (2017). IHC ; Human . PubMed: 27783999
- Absinta M et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elife 6:N/A (2017). PubMed: 28971799
- Wu J et al. Cell cycle activation contributes to increased neuronal activity in the posterior thalamic nucleus and associated chronic hyperesthesia after rat spinal cord contusion. Neurotherapeutics 10:520-38 (2013). WB, IHC . PubMed: 23775067
- Link A et al. Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am J Pathol 178:1662-75 (2011). PubMed: 21435450